Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise

Tirzepatide Showed Superiority To Ozempic In Clinical Trials

Executive Summary

The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade. 

You may also be interested in...



Novo Nordisk’s New Diabetes Combo Shows Potential To Best Lilly’s Mounjaro

New Phase II data shows combination of semaglutide plus a novel amylin analog outperforms semaglutide alone, and could surpass Lilly’s Mounjaro in helping weight loss in diabetes patients.

Novo Touts Diabetes R&D As Ozempic Faces Lilly Challenger

The Danish major highlighted a spate of diabetes pipeline updates during its second quarter earnings as blockbuster drug Ozempic grappled with a new rival in the shape of Lilly’s Mounjaro.

As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan

With Lilly’s sales narrative hampered by global price pressures, Lilly CEO David Ricks again criticized drug price negotiation proposals before Congress. Mounjaro launch offers a bright spot, exceeding projections.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel